Aspira Women's Health Inc.

AWH

US04537Y2081

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 15:08:55 30/04/2024 BST			5-day change	1st Jan Change
3.29 ^USD	-1.20%		-5.31%	-21.32%

04-26	Aspira Women's Health Inc. Announces Minh Merchant Resigns as General Counsel, Chief Compliance Officer, and Corporate Secretary, Effective May 6, 2024	CI
04-01	Cantor Fitzgerald Trims Price Target on Aspira Women's Health to $3.30 From $4, Maintains Neutral Rating	MT

Aspira Women's Health Inc.(NasdaqCM:AWH) dropped from Russell 3000E Value Index

June 25, 2021 at 05:00 am

Latest news about Aspira Women's Health Inc.

Aspira Women's Health Inc. Announces Minh Merchant Resigns as General Counsel, Chief Compliance Officer, and Corporate Secretary, Effective May 6, 2024	04-26	CI
Cantor Fitzgerald Trims Price Target on Aspira Women's Health to $3.30 From $4, Maintains Neutral Rating	04-01	MT
Transcript : Aspira Women's Health Inc., Q4 2023 Earnings Call, Mar 28, 2024	03-28
Earnings Flash (AWH) ASPIRA WOMEN'S HEALTH Posts Q4 Revenue $2.1M	03-28	MT
Aspira Women's Health Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Aspira Women's Health Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-28	CI
Aspira Women's Health Inc. Announces Executive Changes	03-18	CI
Aspira Women's Health Inc. Announces OvaSuite(SM) Distribution Agreement in the Philippines	02-06	CI
Aspira Women's Health Inc. announced that it expects to receive $5.5 million in funding	01-23	CI
Transcript : Aspira Women's Health Inc. - Special Call	01-04
Aspira Women's Health Inc. Announces Resignation of Veronica G.H. Jordan from the Board of Directors	12-27	CI
Aspira Women's Health Provides Development Update on its Portfolio of Noninvasive Tests for Endometriosis	12-06	CI
Aspira Women's Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services	11-27	CI
Transcript : Aspira Women's Health Inc., Q3 2023 Earnings Call, Nov 13, 2023	11-13
Earnings Flash (AWH) ASPIRA WOMEN'S HEALTH Posts Q3 Revenue $2.2M, vs. Street Est of $2.9M	11-13	MT
Aspira Women's Health Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Aspira Women's Health Sees Poster on its MiRNA-Based Ovarian Cancer Test Presented at the AACR Special Conference in Cancer Research	25/10/23	CI
Aspira Women's Health Establishes A New Clinical Advisory Board	23/10/23	CI
Sector Update: Health Care Stocks Mixed Late Afternoon	13/09/23	MT
Sector Update: Health Care Stocks Mixed in Afternoon Trading	13/09/23	MT
Top Midday Gainers	13/09/23	MT
Aspira Women's Health Regains Compliance With Nasdaq Listing Rule	13/09/23	MT
Aspira Women?s Health Announces Executive Changes	11/09/23	CI
Aspira Women's Health Signs Serum Sample Procurement Agreement With University of Oxford	31/08/23	MT
Aspira Women's Health Inc. Signs Exclusive Sample Procurement Agreement with the University of Oxford	31/08/23	CI

Chart Aspira Women's Health Inc.

Duration

Period

More charts

Aspira Women's Health Inc. is engaged in the discovery, development, and commercialization of noninvasive, artificial intelligence (AI)-powered tests to aid in the diagnosis of gynecologic diseases. The Company's portfolio includes OvaWatch and the Ova1Plus workflow, offered to clinicians as OvaSuite. OvaWatch is used to assess ovarian cancer risk for women with an adnexal mass where their initial clinical assessment indicates the mass is indeterminate or benign. The Ova1Plus workflow is designed to assess the risk of ovarian malignancy in women planning for surgery and uses two tests, Ova1 as the primary test and Overa as a reflex for Ova1 intermediate range results. Its in-development test pipeline includes OvaMDxSM risk assessment, EndoCheck and EndoMDx, which are designed to expand its ovarian cancer portfolio and address the tremendous need for noninvasive diagnostics for endometriosis. EndoCheck is a noninvasive test designed to identify endometriomas.

Sector

Biotechnology & Medical Research

Calendar

08/05/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Aspira Women's Health Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

3.33 USD

Average target price

3.3 USD

Spread / Average Target

-0.90%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
ASPIRA WOMEN'S HEALTH INC.	-21.32%	41.12M
EXACT SCIENCES CORPORATION	-19.25%	10.81B
IOVANCE BIOTHERAPEUTICS, INC.	+51.97%	3.36B
GUARDANT HEALTH, INC.	-33.20%	2.22B
BGI GENOMICS CO., LTD.	-14.15%	2.16B
VERACYTE, INC.	-26.68%	1.55B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+20.84%	1.04B
SEEGENE, INC.	-2.62%	746M
CAREDX, INC	-31.08%	425M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-42.86%	405M

Bio Diagnostics & Testing